Insuman Rapid Solostar (Insulin Human)

Insuman Rapid Solostar, a rapid‑acting insulin, works within the glucose regulation pathway to lower blood sugar levels.

• Diabetes mellitus type 1: provides fast‑acting insulin to replace deficient endogenous insulin and achieve glycemic control.
• Diabetes mellitus type 2: supplements insulin therapy when oral agents are insufficient, helping to reach target glucose levels.
• Hyperglycemia in acute care settings: delivers rapid glucose reduction during hospitalised episodes of severe hyperglycaemia.

• Insulin Human binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers downstream signaling cascades, including the PI3‑K/Akt pathway, which promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue. It also suppresses hepatic gluconeogenesis, thereby lowering circulating glucose concentrations. Additionally, insulin facilitates lipid synthesis and protein anabolism, contributing to overall metabolic homeostasis.

Insuman Rapid Solostar may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypoglycaemia: episodes of low blood glucose, especially if meals are missed or dosing is excessive.
• Injection‑site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increased appetite and caloric storage.
• Lipodystrophy: localized fat tissue changes with repeated injections.
• Allergic rash: mild skin eruptions.
• Peripheral oedema: mild swelling of extremities.

Serious or Rare Side Effects

• Severe hypoglycaemia: can lead to loss of consciousness or seizures.
• Anaphylactic reaction: rare but potentially life‑threatening allergy.
• Insulin antibodies: may alter drug effectiveness.
• Hypokalemia: low potassium levels in severe cases.
• Severe local infection: cellulitis or abscess at injection site.
• Acute pancreatitis: very rare inflammatory pancreas condition.

When using Insuman Rapid Solostar, several precautions should be observed to ensure safe and effective therapy.

• Dose adjustment: tailor insulin dose based on self‑monitoring of blood glucose and clinical response.
• Hypoglycaemia risk: educate patients on signs and management of low blood sugar.
• Renal impairment: monitor and possibly reduce dose in patients with reduced kidney function.
• Pregnancy and lactation: use only if benefits outweigh risks and under medical supervision.
• Concomitant medications: assess for drugs that may potentiate hypoglycaemia.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Rapid Solostar can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• MAO inhibitors: can potentiate insulin effect.
• Glucocorticoids: may require higher insulin doses.
• Thiazide diuretics: increase risk of hypoglycaemia.
• Alcohol: can cause unpredictable glucose changes.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance insulin sensitivity.
• Oral hypoglycaemic agents: combined therapy may increase hypoglycaemia risk.
• Thyroid hormones: may alter insulin requirements.
• Growth hormone therapy: may reduce insulin efficacy.